Conversely, in other cancers such as PDAC, hepatocellular cancer (HCC) and GBM, the prognostic implications of RBFOX2 dysregulation contrast with the aforementioned findings. This evidence concerns the gene RBFOX2 and hepatocellular carcinoma.